Drug intelligence / Profile preview

Zhi-Yang Ping-Fu decoction

Development stage: Unknown
Lead developer: China-Japan Friendship Hospital
Administration: Topical

Overview

Zhi-Yang Ping-Fu decoction is a traditional Chinese medicine (TCM) herbal formulation developed by the China-Japan Friendship Hospital for the external treatment of skin toxicities associated with targeted cancer therapies. It is specifically indicated for moderate to severe rashes induced by epidermal growth factor receptor (EGFR) inhibitors, such as those used in the treatment of non-small cell lung cancer. The decoction is applied topically and is designed to alleviate symptoms including pruritus and inflammation, while also potentially modulating the skin microbiota. Clinical evaluation has focused on its efficacy in reducing rash severity and improving patient quality of life compared to standard treatments or placebo.

Other names: Zhiyang Pingfu decoction

Beyond the preview

Go deeper on Zhi-Yang Ping-Fu decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhi-Yang Ping-Fu decoction.

Explore the full profile